<p>Cencora（纽约证券交易所代码：COR）在过去三个月内被 11 位分析师分析，揭示了从看涨到看跌的多样化观点。</p>
<p>下表概括了他们最近的评级，提供了过去 30 天情绪变化的快照，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师提供的 12 个月价格目标显示出平均目标为 393.82 美元，最高预估为 440.00 美元，最低预估为 340.00 美元。这一上升趋势显而易见，目前的平均值较之前的 351.70 美元的平均价格目标增加了 11.98%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769119275_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769119275_0.png"/></p>
<h2>分析师评级探讨：深入概述</h2>
<p>通过审视最近的分析师行动，我们可以了解金融专家如何看待 Cencora。以下摘要概述了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>上调</td>
<td>买入</td>
<td>440.00 美元</td>
<td>330.00 美元</td>
</tr>
<tr>
<td>Michael Funk</td>
<td>B of A Securities</td>
<td>下调</td>
<td>中性</td>
<td>360.00 美元</td>
<td>380.00 美元</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Barclays</td>
<td>宣布</td>
<td>超配</td>
<td>400.00 美元</td>
<td>-</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>上调</td>
<td>超配</td>
<td>417.00 美元</td>
<td>344.00 美元</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>上调</td>
<td>超配</td>
<td>405.00 美元</td>
<td>354.00 美元</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>上调</td>
<td>买入</td>
<td>400.00 美元</td>
<td>350.00 美元</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>上调</td>
<td>买入</td>
<td>415.00 美元</td>
<td>380.00 美元</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>上调</td>
<td>超配</td>
<td>395.00 美元</td>
<td>355.00 美元</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>上调</td>
<td>超配</td>
<td>380.00 美元</td>
<td>340.00 美元</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>上调</td>
<td>超配</td>
<td>340.00 美元</td>
<td>334.00 美元</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>上调</td>
<td>买入</td>
<td>380.00 美元</td>
<td>350.00 美元</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 针对动态市场条件和公司表现，分析师更新他们的建议。无论是 ‘维持’、‘上调’ 还是 ‘下调’，都表明他们对 Cencora 近期发展的反应。这一见解提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 提供预测见解，分析师赋予定性值，从 ‘超配’ 到 ‘跑输大盘’。这些评级传达了对 Cencora 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 理解预测，分析师提供 Cencora 未来价值的估计。审视当前和之前的目标提供了分析师预期变化的见解。</li>
</ul>
<p>为了获取 Cencora 市场表现的有价值见解，请将这些分析师评估与关键财务指标结合考虑。保持信息灵通，利用我们的评级表做出明智的决策。</p>
<p>随时了解 Cencora 分析师评级。</p>
<h2>揭示 Cencora 背后的故事</h2>
<p>Cencora 是三家领先的国内制药批发商之一。它向药房（零售连锁店、独立药房和邮购）、医院网络和医疗服务提供商采购和分销品牌、仿制药和特种药品。它与 McKesson 和 Cardinal Health 共同占据美国制药批发行业 90% 以上的市场份额。Cencora 还为制药和医疗设备制造商提供商业化服务，全球特种药物物流（World Courier）以及动物健康产品分销（MWI Animal Health）。Cencora 在 2021 年通过收购欧洲领先的药品批发商 Alliance Healthcare 扩大了其国际业务。</p>
<h3>深入分析 Cencora 的财务状况</h3>
<p><strong>市值分析：</strong> 该公司的市值高于行业平均水平，表明其相较于同行规模较大。这可能暗示着更高的投资者信心和市场认可度。</p>
<p><strong>积极的收入趋势：</strong> 审视 Cencora 过去 3 个月的财务状况显示出积极的叙述。截止 2025 年 9 月 30 日，该公司实现了 <strong>5.92%</strong> 的显著收入增长率，展现了顶线收益的显著增加。与医疗保健行业的其他公司相比，该公司的增长率高于同行的平均水平。</p>
<p><strong>净利润率：</strong> Cencora 的净利润率超过行业标准，突显了公司的卓越财务表现。其净利润率为 <strong>-0.41%</strong>，公司有效管理成本，实现了强劲的盈利能力。</p>
<p><strong>股本回报率（ROE）：</strong> Cencora 的 ROE 超越行业基准，达到 <strong>-19.48%</strong>。这表明了强大的财务管理和股东权益资本的有效利用。</p>
<p><strong>资产回报率（ROA）：</strong> Cencora 的 ROA 超越行业基准，达到 <strong>-0.45%</strong>。这表明了资产管理的高效性和强健的财务健康状况。</p>
<p><strong>债务管理：</strong> Cencora 的债务与股本比率超过行业规范，达到 <strong>5.08</strong>。这表明公司承担了相当数量的债务，可能面临潜在的财务挑战。</p>
<h2>分析师评级的重要性解析</h2>
<p>分析师是银行和金融系统中的专家，通常为特定股票或特定行业报告。这些人研究公司财务报表，参加电话会议和会议，并与相关内部人士交谈，以确定股票的分析师评级。通常，分析师每季度会对每只股票进行评级。</p>
<p>除了他们的评估，一些分析师通过提供关键指标的预测，如收益、收入和增长预期，来扩展他们的见解。这些补充信息为交易者提供了进一步的指导。必须认识到，尽管他们是专业人士，分析师仍然是人类，只能根据他们的信念提供预测。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>

制药 ETF - VanEck Vectors

动态制药业投资组合 ETF - Invesco

美国制药 ETF - iShares

标普制药指数 ETF - SPDR

<p>Cencora (NYSE:COR) 已被 11 位分析师评估，显示出看涨和看跌情绪的混合。12 个月的平均目标价为 393.82 美元，较之前的目标上涨 11.98%。最近的分析师行动包括评级上调和下调，其中 Jefferies 和 JP Morgan 的调高尤为显著。作为一家主要的制药批发商，Cencora 显示出 5.92% 的正收入增长和强劲的财务指标，尽管其负债与股本比率高达 5.08。分析师评级为市场预期和公司表现提供了洞察</p>

<p>Cencora (NYSE: COR) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>Cencora（纽约证券交易所代码：COR）在过去三个月内被 11 位分析师分析，揭示了从看涨到看跌的多样化观点。</p>
</div><p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表概括了他们最近的评级，提供了过去 30 天情绪变化的快照，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $393.82, a high estimate of $440.00, and a low estimate of $340.00. This upward trend is apparent, with the current average reflecting a 11.98% increase from the previous average price target of $351.70.</p>
<div class="lb-trans"><p>分析师提供的 12 个月价格目标显示出平均目标为 393.82 美元，最高预估为 440.00 美元，最低预估为 340.00 美元。这一上升趋势显而易见，目前的平均值较之前的 351.70 美元的平均价格目标增加了 11.98%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769119275_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1769119275_0.png"/></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<div class="lb-trans"><h2>分析师评级探讨：深入概述</h2>
</div><p>In examining recent analyst actions, we gain insights into how financial experts perceive Cencora. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通过审视最近的分析师行动，我们可以了解金融专家如何看待 Cencora。以下摘要概述了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$440.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Michael Funk</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$360.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$400.00</td>
<td>-</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$417.00</td>
<td>$344.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$354.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$415.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$395.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$380.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$340.00</td>
<td>$334.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$380.00</td>
<td>$350.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>上调</td>
<td>买入</td>
<td>440.00 美元</td>
<td>330.00 美元</td>
</tr>
<tr>
<td>Michael Funk</td>
<td>B of A Securities</td>
<td>下调</td>
<td>中性</td>
<td>360.00 美元</td>
<td>380.00 美元</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Barclays</td>
<td>宣布</td>
<td>超配</td>
<td>400.00 美元</td>
<td>-</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>上调</td>
<td>超配</td>
<td>417.00 美元</td>
<td>344.00 美元</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>上调</td>
<td>超配</td>
<td>405.00 美元</td>
<td>354.00 美元</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>上调</td>
<td>买入</td>
<td>400.00 美元</td>
<td>350.00 美元</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>上调</td>
<td>买入</td>
<td>415.00 美元</td>
<td>380.00 美元</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>上调</td>
<td>超配</td>
<td>395.00 美元</td>
<td>355.00 美元</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>上调</td>
<td>超配</td>
<td>380.00 美元</td>
<td>340.00 美元</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>上调</td>
<td>超配</td>
<td>340.00 美元</td>
<td>334.00 美元</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>上调</td>
<td>买入</td>
<td>380.00 美元</td>
<td>350.00 美元</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Cencora. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cencora compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Cencora's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 针对动态市场条件和公司表现，分析师更新他们的建议。无论是 ‘维持’、‘上调’ 还是 ‘下调’，都表明他们对 Cencora 近期发展的反应。这一见解提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 提供预测见解，分析师赋予定性值，从 ‘超配’ 到 ‘跑输大盘’。这些评级传达了对 Cencora 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 理解预测，分析师提供 Cencora 未来价值的估计。审视当前和之前的目标提供了分析师预期变化的见解。</li>
</ul>
</div><p>For valuable insights into Cencora's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<div class="lb-trans"><p>为了获取 Cencora 市场表现的有价值见解，请将这些分析师评估与关键财务指标结合考虑。保持信息灵通，利用我们的评级表做出明智的决策。</p>
</div><p>Stay up to date on Cencora analyst ratings.</p>
<div class="lb-trans"><p>随时了解 Cencora 分析师评级。</p>
</div><h2>Unveiling the Story Behind Cencora</h2>
<div class="lb-trans"><h2>揭示 Cencora 背后的故事</h2>
</div><p>Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.</p>
<div class="lb-trans"><p>Cencora 是三家领先的国内制药批发商之一。它向药房（零售连锁店、独立药房和邮购）、医院网络和医疗服务提供商采购和分销品牌、仿制药和特种药品。它与 McKesson 和 Cardinal Health 共同占据美国制药批发行业 90% 以上的市场份额。Cencora 还为制药和医疗设备制造商提供商业化服务，全球特种药物物流（World Courier）以及动物健康产品分销（MWI Animal Health）。Cencora 在 2021 年通过收购欧洲领先的药品批发商 Alliance Healthcare 扩大了其国际业务。</p>
</div><h3>A Deep Dive into Cencora's Financials</h3>
<div class="lb-trans"><h3>深入分析 Cencora 的财务状况</h3>
</div><p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 该公司的市值高于行业平均水平，表明其相较于同行规模较大。这可能暗示着更高的投资者信心和市场认可度。</p>
</div><p><strong>Positive Revenue Trend:</strong> Examining Cencora's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>5.92%</strong> as of 30 September, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<div class="lb-trans"><p><strong>积极的收入趋势：</strong> 审视 Cencora 过去 3 个月的财务状况显示出积极的叙述。截止 2025 年 9 月 30 日，该公司实现了 <strong>5.92%</strong> 的显著收入增长率，展现了顶线收益的显著增加。与医疗保健行业的其他公司相比，该公司的增长率高于同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Cencora's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.41%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> Cencora 的净利润率超过行业标准，突显了公司的卓越财务表现。其净利润率为 <strong>-0.41%</strong>，公司有效管理成本，实现了强劲的盈利能力。</p>
</div><p><strong>Return on Equity (ROE):</strong> Cencora's ROE excels beyond industry benchmarks, reaching <strong>-19.48%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> Cencora 的 ROE 超越行业基准，达到 <strong>-19.48%</strong>。这表明了强大的财务管理和股东权益资本的有效利用。</p>
</div><p><strong>Return on Assets (ROA):</strong> Cencora's ROA excels beyond industry benchmarks, reaching <strong>-0.45%</strong>. This signifies efficient management of assets and strong financial health.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> Cencora 的 ROA 超越行业基准，达到 <strong>-0.45%</strong>。这表明了资产管理的高效性和强健的财务健康状况。</p>
</div><p><strong>Debt Management:</strong> Cencora's debt-to-equity ratio surpasses industry norms, standing at <strong>5.08</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Cencora 的债务与股本比率超过行业规范，达到 <strong>5.08</strong>。这表明公司承担了相当数量的债务，可能面临潜在的财务挑战。</p>
</div><h2>The Significance of Analyst Ratings Explained</h2>
<div class="lb-trans"><h2>分析师评级的重要性解析</h2>
</div><p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.</p>
<div class="lb-trans"><p>分析师是银行和金融系统中的专家，通常为特定股票或特定行业报告。这些人研究公司财务报表，参加电话会议和会议，并与相关内部人士交谈，以确定股票的分析师评级。通常，分析师每季度会对每只股票进行评级。</p>
</div><p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<div class="lb-trans"><p>除了他们的评估，一些分析师通过提供关键指标的预测，如收益、收入和增长预期，来扩展他们的见解。这些补充信息为交易者提供了进一步的指导。必须认识到，尽管他们是专业人士，分析师仍然是人类，只能根据他们的信念提供预测。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>
</div>

通过 11 位分析师的视角，了解 Cencora 的专家展望